Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT with Atezolizumab and Chemotherapy in ES-SCLC
NCT04622228Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in small cell lung cancer (SCLC), sponsored by Roche. Primary endpoint: Objective Response Rate at 36 months. Started Dec 2020; status: completed.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04622228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622228.